

HUMAN ANTIBODIES & HYBRIDOMAS

22-24 October 2018, Pullman Riga Old Town Hotel, Riga, Latvia

FIRST CIRCULAR AND CALL FOR PARTICIPATION FOR HAH 2018

Sponsored by the International Journal Human Antibodies · In association with the Integrative Medical Sciences Association

The 21st HUMAN ANTIBODIES & HYBRIDOMAS conference will be held at the Pullman Riga Old Town Hotel in Riga, the capital city of Latvia.

The HAH 2018 scientific programme will have a broadened scope from previous events with the addition of some new topic areas outlined in the scope section below. As usual the scientific programme will include keynote lectures, contributed oral papers and poster presentations emphasising all key aspects of human antibody technologies, applications and engineering.

SCIENTIFIC ADVISORY PANEL

Programme Chairman: Professor Mark Glassy (*UCSD Moores Cancer Center, San Diego, California, USA*)

Mirek Gorny (*New York University School of Medicine, New York, USA*)

Henry Lowman (*CytomX Therapeutics Inc., South San Francisco, California, USA*)

Chris Scott (*The Queen's University, Belfast, Northern Ireland, UK*)

Roberto Burioni (*Universita Vita-Salute San Raffaele, Milan, Italy*)

Jim Larrick (*Panorama Research Inc., USA*)

Alois Lang (*GeNeuro SA, Geneva, Switzerland*)

David P. Humphreys (*UCB, Slough, UK*)

Markus Enzelberger (*MorphoSys AG, Martinsried, Germany*)

Eszter Nagy (*Arsanis GmbH, Vienna, Austria*)

Sachdev Sidhu (*University of Toronto, Canada*)

Neil Brewis (*F-star, Cambridge, UK*)

Paul Kerr (*Fusion Antibodies, Northern Ireland, UK*)

Yan Wu (*Kadmon Pharmaceuticals LLC, New York, USA*)

Bob Kelley (*Genentech Inc., South San Francisco, USA*)

David Naor (*The Hebrew University, Jerusalem, Israel*)

Lynn MacDonald (*Regeneron Pharmaceuticals, Tarrytown, New York, USA*)

Jody Berry (*Becton Dickinson, La Jolla, California, USA*)

Maria Groves (*Medimmune, Cambridge, UK*)

Dale Ludwig (*ImClone Inc., New York, USA*)

Hermann Katinger and Dietmar Katinger

(*Polymun Scientific Immunobiologische Forschung GmbH, Vienna, Austria*)

Andrew Serafini (*Kilpatrick Townsend, Seattle, Washington, USA*)

CONFERENCE SCOPE

The scope of the HAH 2018 conference falls broadly the following main session categories:

**Infectious Diseases · Autoimmunity · Molecular Biology · Emerging Technologies Clinical Applications
Therapeutic Antibodies · Cancer · Anti-Infective Antibodies · Intellectual Property & Legal Issues**

For the 2018 and future meetings the scope is being expanded to include sessions on:

**Formulation · Oral Delivery · Combination Therapy · Validity of Animal Models
Peptide Drugs · Immunotherapy of Cancer & Autoimmunity**



Abstract Submissions

The HAH 2018 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during HAH 2018. The one page abstract should contain sufficient information for the committee to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (HAH 2018 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: **Friday 1st June 2018**. Authors will be informed of the status of their contribution(s) in June 2018.

Closing date for submissions intended for poster presentation: **Friday 5th October 2018**.

Publication

Abstracts of all papers to be presented (oral and poster) will be included on a USB device which will be distributed to delegates on registration. Authors will be invited to submit their papers to the **Human Antibodies Journal**. All submissions will be refereed in the normal fashion and will be published subsequent to the conference.

Participation

All non-invited speakers will be expected to register as delegates to HAH 2018. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at HAH 2018. **Your submission of an abstract testifies to the fact that you will accept these financial conditions.**

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on HAH 2018
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Title (Prof, Dr, Mr, Mrs, Ms): First Name:

Last Name: Organisation:

Address:

Postal/Zip Code: Country:

Telephone: Fax:

E-mail (Please Type/Print):

- My organisation is interested in sponsoring HAH 2018 Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- ANTIBODY/TARGETED-DRUG CONJUGATES** – April 2019, Porto, Portugal
- PLANT-BASED VACCINES ANTIBODIES & BIOLOGICS** – June 2019, Venue to be confirmed

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, HAH 2018, MEETINGS MANAGEMENT

Danehurst, Nore Lane, Hascombe, Godalming, Surrey GU8 4JT, United Kingdom

Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com

Website: www.meetingsmanagement.com/hah_2018